VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
VKTX is developing the candidate in both oral and subcutaneous (SC) formulations for the potential treatment of various metabolic disorders, such as obesity. Viking Therapeutics' phase I maintenance dosing study for VK2735 is aimed at assessing long-term treatment options following initial weight loss. The randomized study has enrolled around 180 otherwise healthy adults with a body mass index of at least 30 kg/m². All participants first receive weekly SC doses of VK2735 or placebo for 19 weeks to induce weight loss. After this lead-in period, patients transition to a range of maintenance regimens, including weekly, biweekly, or monthly SC dosing, as well as daily or weekly oral dosing, or placebo, through week 31. The study is designed to evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 across these dosing strategies, with exploratory endpoints examining changes in body weight from baseline and from Week 19 to the end of the study. The program underscore
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal ObesityPR Newswire
- What Investors Should Know About a Viking Therapeutics Insider's $2 Million Stock Sale [Yahoo! Finance]Yahoo! Finance
- Is Viking Therapeutics (VKTX) Quietly Recasting Its Metabolic Ambitions With VK2735 And New Leadership? [Yahoo! Finance]Yahoo! Finance
- Lightning Round: QXO is a buy, says Jim Cramer [CNBC]CNBC
- Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity [Yahoo! Finance]Yahoo! Finance
VKTX
Earnings
- 10/22/25 - Miss
VKTX
Sec Filings
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- VKTX's page on the SEC website